These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 241721)

  • 1. Purification of soluble complement-fixing antigens from two Burkitt's lymphoma cell lines. Conditions affecting the stability and recovery of antigens and antibodies.
    Weliky N; Leaman DH; Kallman BJ
    Immunology; 1975 Oct; 29(4):779-90. PubMed ID: 241721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability and dissociation of P3H4-1 Burkitt's lymphoma cell soluble complement-fixing antigen identified with human serum.
    Weliky N; Leaman DH; Kallman BJ
    Cancer Res; 1975 Jun; 35(6):1580-5. PubMed ID: 236823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between soluble complement-fixing antigens derived from P3HR-1, RAJI, and Hk-Ly-28 cell lines.
    Weliky N; Leaman DH; Kallman BJ
    J Natl Cancer Inst; 1975 Mar; 54(3):593-6. PubMed ID: 164559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Epstein-Barr virus (EBV) antigens II. Detection of early antigen (S) using anticomplement immunofluorescence (ACIF) et complement fixation (CF) tests.
    Lenoir G; Berthelon MC; Favre MC; De-Thé G
    Biomedicine; 1975 Dec; 23(10):461-4. PubMed ID: 177116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
    Callahan J; Pai S; Cotter M; Robertson ES
    Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytotoxicity induced by the serum of patients with AIDS and at high risk of AIDS against cells infected with Epstein-Barr virus].
    De la Barrera S; Fejes M; Riera NE; Scaglione C; Pérez Blanco R; de Bracco MM
    Rev Argent Microbiol; 1985; 17(3):137-43. PubMed ID: 2829276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface markers.
    Magrath IT; Freeman CB; Pizzo P; Gadek J; Jaffe E; Santaella M; Hammer C; Frank M; Reaman G; Novikovs L
    J Natl Cancer Inst; 1980 Mar; 64(3):477-83. PubMed ID: 6243722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1).
    Klein G; Zeuthen J; Eriksson I; Terasaki P; Bernoco M; Rosén A; Masucci G; Povey S; Ber R
    J Natl Cancer Inst; 1980 Apr; 64(4):725-38. PubMed ID: 6245297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional association of class II antigens with cell surface binding of Epstein-Barr virus.
    Reisert PS; Spiro RC; Townsend PL; Stanford SA; Sairenji T; Humphreys RE
    J Immunol; 1985 Jun; 134(6):3776-80. PubMed ID: 2985696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme-linked immunosorbent assay for antibodies to Epstein-Barr virus-associated early antigens and the viral capsid antigen.
    Dölken G; Boldt C; Lange W; Weitzmann U; Löhr GW; Rosén A
    Cancer Detect Prev; 1983; 6(1-2):287-92. PubMed ID: 6309387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to Epstein-Barr virus (EBV) antigens in sera of American Burkitt lymphoma patients.
    Ablashi DV; De-Thé GB; Easton JM; Liabeuf A; Levine PH; Armstrong GR
    Biomedicine; 1974 Jul; 21(7):288-93. PubMed ID: 4139981
    [No Abstract]   [Full Text] [Related]  

  • 12. Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells.
    Qualtiere LF; Pearson GR
    Int J Cancer; 1979 Jun; 23(6):808-17. PubMed ID: 89099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
    Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
    Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New method for detecting Epstein-Barr virus association in nonproducer lymphoblastoid cell lines.
    Giunta S; Groppa G
    Cancer Res; 1983 Nov; 43(11):5064-7. PubMed ID: 6311404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological evidence for active Epstein-Barr virus infection in multifocal choroiditis.
    Bhende PS; Biswas J; Madhavan HN
    Indian J Pathol Microbiol; 1997 Apr; 40(2):129-31. PubMed ID: 9257497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II. Epstein-Barr virus induction patterns.
    Klein G; Zeuthen J; Ber R; Ernberg I
    J Natl Cancer Inst; 1982 Feb; 68(2):197-202. PubMed ID: 6278188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between Epstein-Barr virus-determined complement-fixing antigen and nuclear antigen detected by anticomplement fluorescence.
    Klein G; Vonka V
    J Natl Cancer Inst; 1974 Dec; 53(6):1645-6. PubMed ID: 4373574
    [No Abstract]   [Full Text] [Related]  

  • 18. [Purification and application of viral capsid antigen of Epstein-Barr virus].
    Zhou W; Gu S
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):252-5. PubMed ID: 15617341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The purification and application of Epstein-Barr virus gp125].
    Wang G; Pi G; Gu S
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun; 12(2):143-6. PubMed ID: 12515193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
    Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
    J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.